- Home
- HCIC vs PROK Comparison
HCIC vs PROK Comparison
Compare HCIC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$1.71
Company Overview
Basic Information| Metric | HCIC | PROK |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.1M | 316.0M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HCIC | PROK |
|---|---|---|
| Price | $9.98 | $1.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 67.0K | ★ 1.2M |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $9.93 | $1.30 |
| 52 Week High | $10.02 | $3.48 |
Technical Indicators
Market Signals| Indicator | HCIC | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 44.50 |
| Support Level | $9.98 | $1.56 |
| Resistance Level | $10.02 | $1.97 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 0.27 | 22.73 |
Price Performance
Historical Comparison HCIC
PROK
About HCIC Hennessy Capital Investment Corp. VIII Class A Ordinary Shares
Hennessy Capital Investment Corp VIII is a blank check company.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.